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Summary
Background: Axl, a member of a family of receptor tyrosine
kinases characterized by an extracellular domain resembling
cell adhesion molecules and an intracellular conserved tyrosine
kinase domain has been reported to induce cell proliferation
and transformation. In mice, axl is expressed in the normal
mammary gland and over-expressed in aggressive mammary
tumors.
Patients and methods: We have investigated the expression
of axl immunohistochemically in 23 normal human breast
samples and in 111 consecutive breast carcinomas. Expression
of axl was correlated with tumour characteristics (lymph node
involvement, stage, grade) and immunohistochemical expres-
sion of ER, PR, Ki-67 and c-erbB-2.
Results: In normal tissue, axl localizes to the membrane of
breast epithelial cells. Axl protein shows membrane associated
staining in high correlation (P = 0.004) with the expression of
the estrogen receptor (ER). Axl expression was found in a
subset of breast carcinomas and was also correlated with high
significance (P < 0.0001) with the presence of ER.
Conclusion: Our results suggest that axl may serve as a
mediator of estrogen stimulation preventing the completion of
the breast epithelial life cycle and that estrogen induced axl
expression may give a survival signal to cancerous cells, pre-
venting them from dying through apoptosis.
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Introduction
Breast cancer is one of the most common malignancies
in women in the Western world with an approximate
probability of one in ten women developing the disease.
The vast majority of breast cancers are sporadic and
their etiology is largely unknown. Exposure to estrogen
has been identified as one of the major risk factors. Early
menarche, regular ovulatory cycles and late menopause
are associated with increased risk for development of
the disease. Prolonged exposure to the periodic develop-
mental processes occurring during the estrous cycle
without subsequent differentiation, like in nulliparity of
late first full-term pregnancy also increases risk [1]. Two
additional observations support the influence of estrogen
on growth control of the breast epithelium. First, the
risk of having breast cancer diagnosed is increased in
women using estrogen during hormone replacement
therapy and this risk increases with the duration of use
[2]. Second, anti-estrogen treatment of women at high
risk for developing breast cancer decreases the incidence
of the disease [3]. A better understanding of the mecha-
nisms controlling hormone-induced growth of the breast
epithelium is desperately needed for the development of
new prognostic and therapeutic tools allowing an im-
proved clinical management of the disease.
The growth of the breast is unique compared to most
other organs beginning its development only through
the hormonal stimulation at puberty. Moreover, end-
differentiation of the breast epithelium is reached only
upon full term pregnancy. In the absence of pregnancy,
hormonal changes throughout the menstrual cycle in-
duce the breast epithelium to limited proliferation, dif-
ferentiation and cell death by apoptosis [4]. Any escape
from this tightly regulated equilibrium of growth and
regression may eventually result in malignant transfor-
mation. Indeed, it has been shown that rat mammary
epithelium (the breast epithelium) is especially prone to
neoplastic development during the follicular phase of the
cycle [5], when estrogen stimulates epithelial prolifera-
tion. As shown for the human breast, the proliferating
epithelial cells themselves do not posses estrogen recep-
tors indicating that the proliferative effect of estrogen is
indirect and requires intercellular mediators [6]. Little,
however, is known about the regulatory mechanisms in
the breast during the menstrual cycle.
It is now well established that protein tyrosine kinases
(PTKs) play an important role in the regulation of
cellular proliferation and differentiation and in the genesis
of many neoplasias. PTKs are generally characterized
as transmembrane receptors or intracellular non-recep-
tor type signal transducers [7]. Ligand binding by the
extracellular domain of the membrane spanning receptor
PTKs activates the intracellular tyrosine kinase domain
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and initiates specific signal transduction pathways [8].
The hormone-responsive regulators of the breast epithe-
lium are largely unknown; however, the established role
of PTKs in the control of cell proliferation makes them
prime candidates for an involvement in mediating
hormone induced growth signals and thus also in the
development of mammary gland neoplasias. Indeed, an
indirect influence of estrogen on PTK has been described
for the epidermal growth factor receptor, the Eph re-
ceptor family member EphB4, and for a non-receptor
tyrosine kinase, iyk [9-12].
In a survey of PTKs expressed in the mouse mammary
gland throughout the estrus cycle, we have analyzed the
RNA expression of the receptor tyrosine kinase ark, the
murine prototype of axl, during mammary gland devel-
opment, the estrous cycle and carcinogenesis [13]. Axl is a
member of a small family of receptors with an extracel-
lular domain resembling cell adhesion molecules and a
conserved tyrosine kinase domain [14]. Axl has been
reported to be implicated in homophilic cell aggregation
[15] and as a receptor for the Gas6 ligand [16]. Further-
more, it has been shown that axl activation induces cell
proliferation and transformation [16]. In mice, axl was
differentially expressed in the normal mammary gland
during the estrous cycle with a maximum at met-estrous.
A strong over-expression could be shown in the aggres-
sively growing Wap-ras-induced mammary tumours
[13]. These observations prompted us to investigate axl
expression in the normal and malignant human breast.
Here, we report that axl expression in normal breast
tissue is restricted to the epithelial component of the
gland, where the axl protein shows membrane associated
staining in high correlation with the expression of the
ER.
TBS (anti-ER, 1:25; anti-progesterone receptor (PR), 1:25; anti-Ki-
67, 1:100). All antibodies were obtained commercially: anti-axl (Santa
Cruz Biotechnology, Santa Cruz, California); anti-ER, anti-PR, anti-
Ki-67, anti-c-erbB-2 (DAKO A/S, Glostrup, Denmark). After three
washes in TBS, sections were incubated with biotinylated swine anti-
rabbit or rabbit anti-mouse antibodies (DAKO) for 1 hr at room
temperature. After three washes in TBS, sections were incubated with
avidin and biotin-horseradish peroxidase complex or alkaline phos-
phatase complex. Peroxidase activity was localized by incubation
in substrate solution [3,3'-diaminobenzidine tablets (Sigma, Buchs,
Switzerland) dissolved in 100 mM imidazole, 100 mM NaCl, 20 mM
citric acid (pH 7.0) containing 0.005% H2OJ for 8 to 10 min at room
temperature. Phosphatase activity was localized by incubation in
naphtol and fuchsine substrate solution for 20 min at room temper-
ature. Sections were counterstained with haemalaun for 30 seconds
and mounted in Aquatex (Merck, Darmstadt, Germany). Control
sections included omission of the primary antibody.
Statistical analysis
The number of immunoreactive cells was semi-quantitatively estimated
by two independent investigators (G.B and H.J.A) who were blinded
with regard to the results of other markers. + corresponded to < 10%
positive cells, ++ to 10%-50% positive cells and +++ to >50%
positive cells. For every sample, at least 100, usually > 1000 cells were
analyzed. Samples with > 10% positive cells were deemed positive.
SAS statistical software was used for statistical analysis. The statistical
significance of differences between individual groups was analyzed
using Fisher's exact test. The relation between the dependent variable
axl and the other independent variables was examined using the multi-
ple logistic regression model for polytomous data with ordinal scale
[17]. The full model was reduced by a backward elimination procedure
to get to the final model. Spearman's rank correlation coefficients were
used to describe pairwise relations between variables c-erbB-2, Ki-67,
PR and ER. Analyses of survival were performed using the Kaplan-
Meier method. Survival distributions were compared with the log-rank
test. P < 0.05 was considered statistically significant.
Results
Patients and methods
Patient material
The material used in this study was taken from patients treated
between August 1997 and May 1999. Malignant breast samples were
obtained from primary breast lesions. The stages of the invasive
carcinomas were classified as based on the TNM classification. For
normal human breast samples, tissue specimens were obtained from
reduction mammoplasties. The hormonal state of the patients were
determined by questioning. Patients receiving hormonal substitution
or with unclear cyclic states were not included in this study. This study
was approved by the ethical commission of the University of Berne.
Immunohistochemistrv
Breast tissue specimens were fixed in 4% formaldehyde and paraffin-
embedded; 4 urn sections from the same sample were de-waxed,
rehydrated and washed 3 times for 5 min at room temperature in TBS
(25 mM Tris-HCl, pH 7.5; 140 mM NaCl). Sections were boiled in a
microwave oven in 10 mM citrate buffer, followed by washing in TBS (3
times for 5 min), and endogenous peroxidase was blocked by incuba-
tion in 0.3% H2O2 in TBS for 10 min at room temperature. Incubation
with the primary antibodies was done overnight at 4°C. Antibodies
were diluted in either 5% TNA (50 mM Tris-HCl, 140 mM NaCl, 0.5%
Na caseinate, 15 mM NaN3) (anti-axl, I; 100; anti-c-erbB-2, 1 : 50) or
Expression in the normal human breast
We have investigated axl expression in normal human
breast specimens at the proliferating follicular and the
differentiating luteal phases of the menstrual cycle, as
well as at the resting phase after menopause. Tissue
specimens were obtained from 23 normal human breast
samples including 6 post-menopausal and 17 pre-meno-
pausal patients. Twelve patients were in the follicular
phase of the menstrual cycle and five in the luteal phase.
The mean age of these 23 patients was 40.3 ± 12.5 years
(range 18-70). All pre-menopausal patients had a cycle
time between 28 and 31 days.
These experiments revealed that axl is exclusively
expressed in the breast epithelium. No axl protein was
detected in myo-epithelial cells, fibroblasts surrounding
the breast parenchyma or in fibro-adipose tissue. In the
epithelial cells, membrane associated staining was seen
(Figure la). This staining was not present when the first
antibody was omitted. During the follicular phase of the
menstrual cycle, a higher number of epithelial cells was
axl positive compared to the luteal phase. As hormonal
status strongly influences the physiology of the breast,
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Figure I. Localization of axl protein and estrogen receptor (ER) in Figure 2. Axl and estrogen receptor (ER) expression in an invasive
normal breast tissue. Sections were reacted with anti-axl (a) or anti-ER ductal carcinoma. Sections were reacted with anti-axl (a) or anti-ER
antibodies (b), visualized with alkaline phosphatase (a) or horse radish antibodies (b), visualized with alkaline phosphatase (a) or horse radish
peroxidase (b). Scale bars = 50 | j . peroxidase (b). Scale bars = 50 u.
we have analyzed the expression of ER (Figure lb)
which was found more often during the follicular than
during the luteal phase of the cycle (P = 0.046). Strikingly,
we have found a highly significant association (P = 0.004)
of axl positivity with the ER status in the normal human
breast epithelial cells.
Expression of axl in malignant disease of the human
breast
The analysis of the normal human breast has indicated a
strong correlation between axl and ER expression.
Although being far from unerring, the status of the ERs
is the most relevant factor predicting treatment response
to endocrine therapy in breast cancer [18]. We have there-
fore investigated axl expression as a potential mediator
of estrogen stimuli in malignant disease of the breast.
Malignant breast samples included 111 consecutive inva-
sive carcinomas (87 ductal, 20 lobular, 3 mucinous and 1
medullary carcinomas) and 3 ductal in situ carcinomas.
The clinical stages of the invasive carcinomas were
classified as follows: 55 as pTl, 44 as pT2, 10 as pT3 and
2 as pT4. Eight (7%) of our patients tumours were
classified as grade 1, 78 (68.4%) as grade 2 and 28
(24.6%) as grade 3. Lymph-node dissection was per-
formed on 99 patients with invasive carcinoma, 40 of
whom were positive for metastases. Mean age at diag-
nosis for the carcinoma group was 59.4 ± 13.5 years
(range 31-81) and 81 from 114 patients (71%) were post-
menopausal. The median follow-up of the patients with-
out recurrence is 25 ± 8 months (11-42 months).
Immunohistochemical staining revealed membrane
localization of the axl protein in neoplastic cells of a
subset of tumours analyzed. Like in the normal breast,
we observed a high correlation between axl and ER
expression (Figures 2a and 2b). These results, including
the results of immunohistochemical analysis of PR
expression, are summarized in Table 1. Interestingly, axl
expression was only found in ER positive tumours,
however, not all ER positive tumours expressed the axl
protein.
Relation between axl expression and prognostic markers
In a multiple logistic regression (Table 2), we could find
a highly significant relation between axl positivity and
ER (P < 0.0001). A significant relation was also found
between axl and the tumour stage (P = 0.006) and the
immunohistochemical expression of the proliferation
marker Ki-67 (P = 0.022). There was no relation with
other prognostic factors, such as grade of tumour
(P = 0.711), lymph node involvement (P = 0.740), and PR
expression (P — 0.414) or with the clinical outcome such
as shorter disease-free survival (P = 0.94). As expected,
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Table 1. Epithelial expression of axl
progesterone receptors (PR) in human
Axl
ER
PR
Table
nostic
< 10% l l%-
37 38
27 16
44 28
, estrogen receptors
breast carcinomas.
50% > 50%
39
71
42
2. Relation between membrane accumulation of axl
: factors in breast cancer (n = 113).
Iti° Chi-squareb
(ER) and
n
114
114
114
and prog-
P-value
Summary of backward elimination
Grade of tumour (G)
Menopause
PR
Age
Final model
Tumour stage
Ki-67
ER
6
5
4
3
0.68
0.60
0.66
1.45
14.12
5.23
29.84
0.711
0.438
0.414
0.227
0.006
0.022
< 0.0001
" Number of independent variables remaining in the model after the
examined variable is removed from the model. Value of the statistic test
to calculate the /'-value.
The relevant parameters for the antibody staining of axl (+/++/+++)
were examined using the multiple logistic regression model for polyto-
mous data with ordinal scale [17]. The full model (grade of tumour, 1/
2/3; menopause, yes/no; PR, + /++/+++; age, years; tumour stage,
pTis to pT4; Ki-67, + /++/+++; ER, +/++/+++) was reduced by a
backward elimination to the final model. The final model provides a set
of variables that have a high influence on the dependent variable axl.
there was a strong association of ER status with PR
status (P = 0.0001) and a significant inverse relationship
between ER status and Ki-67 (P = 0.008) or c-erbB-2
(P = 0.002) (Table 3).
Discussion
The immunohistochemical investigation of normal breast
tissue has revealed that the axl protein, the human
homologue of mouse ark, localizes in the membrane of
the epithelial cells. Expression of proteins of the axl
family is predominantly localized to the central nervous
system, but they are also notably expressed in many
non-neural tissues such as kidney, spleen, ovary and
testis [14]. In tissue culture, axl is expressed in different
cell lines of epithelial cell origin [19]. In the mouse
mammary gland, the expression of a family member, sky,
is regulated during pregnancy, lactation and involution,
suggesting its involvement in normal mammary gland
development [20]. Furthermore, axl shows a differential
expression during the estrous cycle, supporting the
postulated role in normal mammary gland physiology
[13]. In mouse mammary tumours, a possible involvement
in invasive carcinogenesis is suggested by the strong
over-expression of axl only in the aggressively growing
Wap-ras induced mammary tumours and by the expres-
sion in several human breast cancer cell lines [13]. More-
Table 3 Correlation between antibody staining of estrogen receptors
(ER), progesterone receptors (PR) and new prognostic factors (Spear-
man's rank test).
Correlation-coefficient (two-tailed P-value)
ER PR Ki-67 c-erbB-2
ER(n = 114)
PR(n = 114)
Ki-67 (n = 113)
c-crbB-2(n = 105)
1.000 (-)
0 435(0 0001)
-0.246 (0 008)
-0.302 (0 002)
1.000 (-)
-0.233(0.013)
-0 166(0.091)
1.000 (-)
0.215(0 028) 1 000 (-)
over, strong expression in mouse mammary tumours
and overexpression in a tumourigenic human breast cell
line has been described for the other family member, sky
[20]. In our study, axl was localized in the membrane of
the human breast cancer cells and the number of cells
expressing axl was found to be higher in cancerous tissue
than in the normal breast (P < 0.001). Overexpression
of axl has also been observed in a metastatic sample of a
colon cancer [21].
We have found a significant association {P = 0.004)
of axl positivity with the ER status in normal human
epithelial breast cells and in breast cancer cells. In the
mouse mammary gland, axl was already detected in
immature females but showed a maximal expression in
mature females during the estrous and the met-estrous
phase, characterized by maximal estrogen secretion.
During an estrous, which is characterized by alveoli with
a flattened epithelium, regional cell death and minimal
estrogen secretion, only low axl expression was detected
[13]. We have also observed a higher expression of ER
and axl during the estrogen dominated follicular phase
of the cycle in the human breast, but this difference was
statistically not significant. This result is not surprising
since the developmental processes occurring in the
breast during the menstrual cycle involve only a subset
of lobular structures [22]. Furthermore, it has been
shown that the percentage of cells which express ER in
the normal human breast not only varies throughout the
menstrual cycle but also greatly varies during the different
phases of the cycle [23]. Our results suggest the impor-
tance of estrogens for the presence of axl proteins.
Although the effect of progesterone on the expression of
axl expression remains to be investigated, the onset of
its expression in immature mouse females, when proges-
terone is not yet active [24], the high expression in the
follicular phase and the absence of association with PR
in breast cancers support the notion that estrogen repre-
sents the main inducer of axl protein.
In a recent study, the influence of estrogens on another
receptor PTK, EphB4 was demonstrated [10]. An indi-
rect effect of the activated estrogen receptor on the
translation and/or stabilization of the EphB4 receptor
and its ligand has been suggested. Estrogens can also
promote the autocrine expression of insulin-like growth
factor-II (IGF-II) [25] and epidermal growth factor
receptor (EGFR) [26] and interact with both c-erbB2
protein and the nuclear receptor by a similar molecular
823
mechanism [27]. Thus, the interactions between steroid
hormone receptors and receptor PTKs may be of impor-
tance for modulation and/or targeting of hormone
induced signals.
Axl was first isolated as an oncogene with a weak
oncogenic activity and transformation could only be
observed in cells overexpressing axl protein [19]. Further-
more, very high doses of Gas6, the ligand of axl have
been shown to induce cell proliferation [14, 28]. This
weak mitogenic activity is supported in our study by the
association (P = 0.022) between axl and the proliferation
index determined by the expression of Ki-67 in breast
cancer. Interestingly, constitutive expression of Gas6 in
NIH3T3 prevents cell from undergoing apoptosis without
inducing cell proliferation [29]. Cell death or apoptosis in
serum deprived growth arrested NIH3T3 cells is also
prevented by addition of Gas6 and this effect is inde-
pendent of its mitogenic activity [28]. Furthermore,
embryonic fibroblasts from axl knock-out mice are highly
susceptible to apoptosis induced by serum deprivation
[29]. As the antiapoptotic effect of Gas6 is reached at
concentrations ten times lower than those needed to
stimulate mitogenesis, it is possible that the true role of
axl signaling consists in promoting cell survival [29].
Our results indicate that ER probably induce axl expres-
sion and this interaction could play an important role in
the proliferation, differentiation and apoptotic cell death
in human breast epithelium during the menstrual cycle.
Conceivably, increased local estrogen activity inducing
axl expression may be a trigger of mammary carcino-
genesis by giving a survival signal to cancerous cells,
preventing them from apoptotic cell death and thereby
from completion of their life cycle. This promotion of
cell survival is realized under conditions which do not
involve high cell proliferation.
Bcl-2 is one of the few genes thought to be involved in
the control of cell survival and cell death during the
estrous cycle [4]. Like axl, expression of the bcl-2 gene
has been shown to counteract apoptosis and to prolong
cell survival without affecting cell proliferation [30].
Consistent with this potential to inhibit apoptosis,
overexpression of bcl-2 in Wap- bcl-2 mice was able to
complement an increased expression of myc and pro-
mote mammary tumorigenesis. Anti-estrogen treatment
is associated with increased apoptosis in hormone-
dependent breast cancer cell lines growing in vitro or in
vivo [31, 32]. The anti-estrogen tamoxifen possesses the
ability to induce apoptosis in the estrogen dependent
breast cancer cell line MCF-7 probably through down-
regulation of bcl-2 expression [33]. It remains to be
elucidated, if the ER induced axl signaling is involved in
the control of anti-apoptotic proteins such as bcl-2.
In summary, our results revealed a strict dependence
of axl expression on the presence of ER. The fact that
not all ER positive cells were also positive for the axl
protein suggests that this cell population has distinct
properties than the axl negative ones. This fact also raises
the possibility that axl expression influences the response
of cancer cells to anti-estrogen treatment. It remains to
be elucidated if axl expression may represent a novel
marker predicting the response of ER positive tumours
to hormonal therapy. These studies, however, require
further retrospective investigations including a larger
number of patients with a longer follow-up than it was
used in this pilot study.
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